Skip to content

Bioalmanac

5-Amino-1MQ

5-Amino-1-methylquinolinium · 5A1MQ

Preclinical

Status reviewed 16 Aug 2026

An oral NNMT inhibitor with striking results in obese mice and no human data whatsoever. Not a peptide, despite where it is sold.

Storage

Freeze-dried powder
Capsules or powder at room temperature, dry and out of direct light.
After mixing
Not applicable. This is taken orally, not reconstituted.

Dose ranges reported in sources

Descriptions of what sources report, not recommendations.

GoalRangeFrequencySource
Commonly sold capsule strength50000–150000 mcgOnce daily, often described in courses of several weeksManufacturer

When to stop

  • Any allergic response: rash, hives, facial swelling or difficulty breathing. Seek urgent care.
  • Yellowing of the skin or eyes, dark urine, or pain in the upper right abdomen. NNMT is highly expressed in the liver, and nothing establishes what inhibiting it there does.
  • Persistent nausea, headache or fatigue.
  • Any new lump or unexplained persistent symptom.

Not approved anywhere, for any purpose, and never studied in a published human trial. Sold as a capsule, often labelled as a dietary supplement or a research chemical. Neither category requires evidence of effect or safety before sale.

Arithmetic on values you enter. Not medical advice. Not reviewed by a clinician. · bioalmanac.com/peptides/5-amino-1mq

Use your browser’s print dialog and choose “Save as PDF”. This block is hidden when printed.